Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
16 juil. 2018 06h59 HE
|
Spero Therapeutics, Inc.
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...
Spero Therapeutics Announces Pricing of Securities Offering
12 juil. 2018 20h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Proposed Offering of Common Stock
09 juil. 2018 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
09 juil. 2018 07h30 HE
|
Spero Therapeutics, Inc.
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending dosesData support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to...
Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
05 juin 2018 08h00 HE
|
Spero Therapeutics, Inc.
Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass., June 05, 2018 ...
Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
01 juin 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
23 mai 2018 08h00 HE
|
Spero Therapeutics, Inc.
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and...
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
10 mai 2018 16h05 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
01 mai 2018 09h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
16 avr. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...